ESC guidelines for the diagnosis and management of chronic coronary syndromes (CCS) recommend ACE inhibitors (or ARBs in case of ACE inhibitor intolerance) in patients at high cardiovascular risk because of coexisting conditions such as hypertension, LVEF ≤ 40%, diabetes, or CKD, but not for vascular protection per se [46]. The gene discussed is ACE; the disease is chronic kidney disease.